Q1 Earnings Estimate for Inozyme Pharma Issued By Wedbush

Inozyme Pharma, Inc. (NASDAQ:INZY) – Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Inozyme Pharma in a research note issued to investors on Monday, March 10th. Wedbush analyst D. Nierengarten expects that the company will earn ($0.43) per share for the quarter. Wedbush has a “Outperform” rating and a $7.00 price objective on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share. Wedbush also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.15) EPS, FY2026 earnings at ($1.01) EPS and FY2027 earnings at ($0.80) EPS.

Several other research analysts also recently commented on INZY. Raymond James decreased their price objective on Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating on the stock in a research note on Wednesday. Piper Sandler decreased their target price on Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Inozyme Pharma in a research note on Tuesday. Needham & Company LLC decreased their target price on Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Wells Fargo & Company decreased their target price on Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $14.56.

Inozyme Pharma Stock Down 7.4 %

NASDAQ INZY opened at $1.00 on Thursday. The stock’s 50-day moving average price is $1.48 and its 200-day moving average price is $3.26. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma has a 52 week low of $0.98 and a 52 week high of $7.80. The company has a market capitalization of $64.22 million, a P/E ratio of -0.64 and a beta of 1.32.

Institutional Trading of Inozyme Pharma

Large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC increased its position in shares of Inozyme Pharma by 7.5% during the 3rd quarter. Jane Street Group LLC now owns 49,460 shares of the company’s stock valued at $259,000 after purchasing an additional 3,443 shares during the last quarter. OneDigital Investment Advisors LLC increased its position in shares of Inozyme Pharma by 51.5% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 20,000 shares of the company’s stock valued at $105,000 after purchasing an additional 6,800 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Inozyme Pharma by 31.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company’s stock valued at $151,000 after purchasing an additional 6,851 shares during the last quarter. Palumbo Wealth Management LLC increased its position in shares of Inozyme Pharma by 52.3% during the 4th quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company’s stock valued at $64,000 after purchasing an additional 7,995 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Inozyme Pharma by 11.6% during the 4th quarter. American Century Companies Inc. now owns 79,349 shares of the company’s stock valued at $220,000 after purchasing an additional 8,263 shares during the last quarter. Institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.